Use of in vivo and in vitro systems to select leishmania amazonensis expressing green fluorescent protein

Korean Journal of Parasitology

Volumn 49, Issue 4, 2011, Pages 357-364

  dos Santos Costa, Solange ^a   de Assis Golim, Marjorie ^a   Rossi Bergmann, Bartira ^b   Costa, Fabio Trindade Maranhão ^c   Giorgio, Selma ^a  

^a UNIVERSITY OF CAMPINAS   (Brazil)

^b SÃO PAULO STATE UNIVERSITY UNESP   (Brazil)

^c FEDERAL UNIVERSITY OF RIO DE JANEIRO   (Brazil)

Author keywords

Geneticin; Green fluorescent protein; Leishmania amazonensis; Macrophage

Indexed keywords

GREEN FLUORESCENT PROTEIN;

AMASTIGOTE; ANIMAL CELL; ANTIBIOTIC SENSITIVITY; ARTICLE; CONTROLLED STUDY; EPISOME; IN VITRO SELECTION; LEISHMANIA; MACROPHAGE; MOUSE; NONHUMAN; PLASMID; PROMASTIGOTE;

GENETICIN; GREEN FLUORESCENT PROTEIN; LEISHMANIA AMAZONENSIS; MACROPHAGE;

AMEBICIDES; ANIMALS; FLOW CYTOMETRY; GENTAMICINS; GREEN FLUORESCENT PROTEINS; HOST-PARASITE INTERACTIONS; LEISHMANIA MEXICANA; LEISHMANIASIS, CUTANEOUS; LUMINESCENT AGENTS; MACROPHAGES, PERITONEAL; MICE; MICE, INBRED BALB C; ORGANISMS, GENETICALLY MODIFIED; SPECTROMETRY, FLUORESCENCE;

LEISHMANIA AMAZONENSIS; MAMMALIA; MUS;

EID: 84855512536     PISSN: 00234001     EISSN: 17380006     Source Type: Journal    
DOI: 10.3347/kjp.2011.49.4.357     Document Type: Article

References (23)

1. Ha DS, Schwarz JK, Turco SJ, Beverley SM. Use of the green fluorescent protein as a marker in transfected Leishmania. Mol Biochem Parasitol 1996; 77: 57-64.
2. Misslitz A, Mottram JC, Overath P, Aebischer T. Targeted integration into a rRNA locus results in uniform and high level expression of transgenes in Leishmania amastigotes. Mol Biochem Parasitol 2000; 107: 251-261.
3. Sereno D, Roy G, Lemesre JL, Papadopoulou B, Ouellette M. DNA transformation of Leishmania infantum axenic amastigotes and their use in drug screening. Antimicrob Agents Chemother 2001; 45: 1168-1173.
4. Kamau SW, Grimm F, Hehl AB. Expression of green fluorescent protein as a marker for effects of antileishmanial compounds in vitro. Antimicrob Agents Chemother 2001; 45: 3654-3656.
5. Chan MM, Bulinski JC, Chang KP, Fong D. A microplate assay for Leishmania amazonensis promastigotes expressing multimeric green fluorescent protein. Parasitol Res 2003; 89: 266-271.
6. Okuno T, Goto Y, Matsumoto Y, Otsuka H, Matsumoto Y. Applications of recombinant Leishmania amazonensis expressing egfp or the beta-galactosidase gene for drug screening and histopathological analysis. Exp Anim 2003; 52: 109-118.
7. Singh N, Gupta R, Jaiswal AK, Sundar S, Dube A. Transgenic Leishmania donovani clinical isolates expressing green fluorescent protein constitutively for rapid and reliable ex vivo drug screening. J Antimicrob Chemother 2009; 64: 370-374.
8. Varela M RE, Muñoz DL, Robledo SM, Kolli BK, Dutta S, Chang KP, Muskus C. Leishmania (Viannia) panamensis: An in vitro assay using the expression of GFP for screening of antileishmanial drug. Exp Parasitol 2009; 122: 134-139.
9. Singh N, Dube A. Short report: fluorescent Leishmania: application to anti-leishmanial drug testing. Am J Trop Med Hyg 2004; 71: 400-402.
10. Kain SR. Green fluorescent protein (GFP): Applications in cell-based assays for drug discovery. Drug Discov Today 1999; 4: 304-312.
11. Mehta SR, Huang R, Yang M, Zhang XQ, Kolli B, Chang KP, Hoffman RM, Goto Y, Badaro R, Schooley RT. Real-time in vivo green fluorescent protein imaging of a murine leishmaniasis model as a new tool for Leishmania vaccine and drug discovery. Clin Vaccine Immunol 2008; 15: 1764-1770.
12. Roy G, Dumas C, Sereno D, Wu Y, Singh AK, Tremblay MJ, Ouellette M, Olivier M, Papadopoulou B. Episomal and stable expression of the luciferase reporter gene for quantifying Leishmania spp. infections in macrophages and in animal models. Mol Biochem Parasitol 2000; 110: 195-206.
13. Shimony O, Jaffe CL. Rapid fluorescent assay for screening drugs on Leishmania amastigotes. J Microbiol Methods 2008; 75: 196-200.
14. Grimaldi G Jr, Tesh RB. Leishmaniases of the new world: Current concepts and implications for future research. Clin Microbiol Rev 1993; 6: 230-250.
15. Desjeux P. Leishmaniasis: Current situation and new perspectives. Comp Immunol Microbiol Infect Dis 2004; 27: 305-318.
16. Rossi-Bergmann B, Lenglet A, Bezerra-Santos CR, Costa-Pinto D, Traub-Czeko YM. Use of fluorescent Leishmania for faster quantitation of parasite growth in vitro and in vivo. Mem Inst Oswaldo Cruz 1999; 94: 74.
17. Arrais-Silva WW, Pinto EF, Rossi-Bergmann B, Giorgio S. Hyperbaric oxygen therapy reduces the size of Leishmania amazonensis-induced soft tissue lesions in mice. Acta Trop 2006; 98: 130-136.
18. Boeck P, Bandeira Falcão CA, Leal PC, Yunes RA, Filho VC, Torres-Santos EC, Rossi-Bergmann B. Synthesis of chalcone analogues with increased antileishmanial activity. Bioorg Med Chem 2006; 14: 1538-1545.
19. Colhone MC, Arrais-Silva WW, Picoli C, Giorgio S. Effect of hypoxia on macrophage infection by Leishmania amazonensis. J Parasitol 2004; 90: 510-515.
20. Naumov GN, Wilson SM, MacDonald IC, Schmidt EE, Morris VL, Groom AC, Hoffman RM, Chambers AF. Cellular expression of green fluorescent protein, coupled with high-resolution in vivo videomicroscopy, to monitor steps in tumor metastasis. J Cell Sci 1999; 112: 1835-1842.
21. Wade-Martins R, Frampton J, James MR. Long-term stability of large insert genomic DNA episomal shuttle vectors in human cells. Nucleic Acids Res 1999; 27: 1674-1682.
22. Murphy NB, Muthiani AM, Peregrine AS. Use of an in vivo system to determine the G418 resistance phenotype of bloodstream-form Trypanosoma brucei brucei transfectants. Antimicrob Agents Chemother 1993; 37: 1167-1170.
23. Appel KF, Wolff AM, Arnau J. A multicopy vector system for genetic studies in Mucor circinelloides and other zygomycetes. Mol Genet Genomics 2004; 271: 595-602.